Aktiebolaget Segulah and Segulah Venture AB participating in Senzime AB’s directed equity issue

Aktiebolaget Segulah and Segulah Venture AB have subscribed to a total of 668,877 shares in Senzime AB.

Senzime develops unique medical devices that enable patients’ biochemical and physiological processes to be monitored before, during, and after surgery.

The company’s solutions aim to ensure maximum patient benefit, reduce surgical complications, and cut healthcare costs. Senzime operates in growing markets, with Europe and the US alone currently valued at over SEK 10 billion.

Following this transaction, the Segulah Group holds 3,818,877 shares in Senzime AB.

Senzime stock is listed on NASDAQ Stockholm First North

For additional information, please contact

Lennart Kalén, Vice-Chairman Aktiebolaget Segulah, +46 70 536 26 00.